4th Edition MarketsandMarkets Genome Editing & Gene Therapy Conference

4th Edition MarketsandMarkets Genome Editing & Gene Therapy Conference is organized by MarketsandMarkets (MnM) Conferences and will be held from Feb 06 - 07, 2020 at San Diego, California, United States of America.

Who should Attend?
• Professors
• Lecturers Research scientist/fellows from Universities and Research Institutes from departments of: 
? Genome editing
? Genome engineering
? Functional genomics
? Gene therapy
? Cell therapy
? Disease modeling
? Gene regulation
? Heads
? Chief scientific officers
? Research scientists
? Laboratory managers from pharmaceuticals
• bio-pharma and therapeutics companies from departments of: 
? Genome biology
? Drug discovery and R&D
? Genetics
? Computational biology
? Gene & Cell therapy

Description:
Since our past editions we dedicated our focus on the latest developments and addressed various applications of CRISPR as a molecular tool, gene expression, knock-in, genomic screening, along with therapeutic developments through animal modeling. Attended by 100 genome editing professionals and 20 gene expert speakers, the event saw participation of big companies like Casebia Therapeutics, Genentech, BMS, Cellectis , University of Laval, University of California, Center of Advanced Genome Engineering, Georgia Tech, Stanford University, Locana, Harvard Medical School, Agility, Poseida, Vertex, Ligandal, Integrated DNA Technologies, GE Healthcare, Cellecta, Agilent, Advanced Analytical, Thermofisher, Atum, Synthego, New England Biolabs, Aldevron, Applied Stem Cell and more.

They are getting ahead by discussing the commercialization and advancements of technology which will outline breakthrough advancements in pre-clinical & clinical therapeutics using genome Editing. The event will also focus on analysis of off target effects, specificity and aspects of gene and cellular therapies.

Key Highlights:
• Allogenic Car-T cells
?• Off target effects
• Stem cell immunotherapy
• Specificity of CRISPR
• Multiplexity of genes
• Viral and non-viral gene delivery
• Ethical issues
• T-cell proliferation
• DNA repair & DNA toxicity removal
• Next-gen cell and gene therapy
• Electroporation and cell engineering

Additional details will be posted as soon as information is available.